A Phase 1 interventional study of NNC9204-1513 and Glucagon in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-05.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 366th largest by enrollment of the 494 interventional ones that give a count, is one of 5 that started in 2018, is one of 206 in phase 1, and was the 635th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–75
Novo Nordisk A/S · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
642 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 87 across the 494 interventional studies, 1,497 across the 148 observational. Of the 636 that completed or were terminated, 163 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Diabetes Mellitus by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07535307Novo Nordisk A/SInvestigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes | 2027-11-11 |
Add it to your calendar (.ics) → With an account.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
Participants will either receive NNC9204-1513 or GlucaGen® - which treatment you get is decided by chance (like flipping a coin). Neither the participant nor the study doctor will know which study medicine (NNC9204-1513 or GlucaGen®) the participant is receiving (double -blinding). In case of emergency, this information will be readily available.
NNC9204-1513 is a new medicine for rescue treatment of severe low blood sugar and currently not available on the market (doctors cannot prescribe this medicine). The participant will receive two or three single injections below the skin. One injection will contain NNC9204-1513 or GlucaGen®. The other injection will include placebo - this is a product that looks like the actual study drug but without any active ingredients. If a third injection is given, this will contain NNC9204-1513 or placebo. NNC9204-1513 and GlucaGen® will be given using different devices and volumes. In order to mask these external differences, a "double dummy" approach will be used, that means when you get either of the study medicine (NNC9204-1513 or GlucaGen®) you will get another injection which contains no medicine called 'placebo' (it will not have any effect on the body). Dependent on the injection volume to be administered, injections are given by either syringe with needle or an injection pen (NovoPen Echo®). The study will last for up to 39 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive increasing doses of NNC9204-1513.
Drug: NNC9204-1513 · Drug: Placebo
Participants will receive a single fixed dose of glucagon.
Drug: Glucagon · Drug: Placebo
Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose. Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Participants will receive single dose of 1 mg glucagon s.c. injection.
Also known as: GlucaGen®
Participants will receive single dose of placebo (for double dummy injections).
Number of treatment emergent adverse events (TEAEs)
Count of events
Time frame: from time of dosing (day 1) to completion of the safety follow-up visit (day 8)
Change from baseline in haematology
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in biochemistry
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in fibrinogen
measured in g/L
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in lipids
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in glucose metabolism
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in hormones
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in urine dipstick parameter
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in systolic- and diastolic blood pressure
Measured in mm Hg
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in body temperature
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in respiration rate
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in 12-lead electrocardiogram (ECG) heart rate
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in 12-lead ECG (RR interval)
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in 12-lead ECG (PR interval)
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in 12-lead ECG (QRS interval)
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in 12-lead ECG (QT interval)
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in 12-lead ECG (QTc intervals [Fridericia])
QT interval corrected for heart rate by Fridericia's formula
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in Physical examination
Time frame: baseline (day 1), follow-up visit (day 8)
Incidence of injection site reactions
Time frame: After administration of the trial products (day 1) until completion of the post-treatment follow-up visit (day 8).
AUC0-15min,SD, area under the plasma concentration time curve
Time frame: 0 to 15 minutes after single dose
t1/2,SD, terminal half-life
Time frame: Measured for 24 hours after administration of a single s.c. dose
Onset of appearance
Time from trial product administration until first time plasma concentration ≥ lower limit of quantification (LLOQ)
Time frame: Measured for 24 hours after administration of a single s.c. dose
AUCPG,0-15min,SD, area under the plasma glucose time curve
Time frame: 0 to 15 minutes after single dose
ΔPG0-15min,SD, Increase in plasma glucose concentration from 0 to 15 minutes
Calculated as: Plasma glucose concentration at 15 minutes after single dose minus plasma glucose concentration at 0 minute
Time frame: 0 to 15 minutes after single dose
Change from baseline in 12-lead ECG (overall evaluation)
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in prothrombin time
measured in seconds
Time frame: baseline (day 1), follow-up visit (day 8)
Change from baseline in Activated Partial Thromboplastin time (APTT)
measured in seconds
Time frame: baseline (day 1), follow-up visit (day 8)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · www.novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in May 2018, 3 months.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 3 months is below that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.